I would expect an incremental change in share price as results start coming in. Better results in NASH should bump it, BTDs, results from the full trial in Brazil if not the interim. If we can get an EUA on Covid trials results in either Brazil or the Philippines then the bleeding stops. But I wouldn't count on that. But even the incremental increases should mean well over $300 million if needed.

We could also screw ourselves over slightly in the long run by cutting a bad deal overseas. In overseas deals you can either take no cash upfront and a good percentage or cash and a bad percentage. In small markets you're unlikely to get any cash upfront so you'd want to get a deal in a medium sized market. Japan is an ideally sized market and with a cancer BTD and good NASH results we could probably get $30 - $40 million upfront with a 20% cut. But with a 20% cut on all indications that's a lot of money lost.